Susie Lisa

“On tonight's call, making prepared remarks, we have Dr. Reshma K. Walramani, Vertex's CEO and President, Charlie Wagner, Chief Operating Officer and Chief Financial Officer, and Duncan McKechnie, Chief Commercial Officer.”

“Thank you very much to everyone here in the room for finding us, despite locked doors and escalators and challenging room locations. We really appreciate it. Obviously, a very, very exciting ASN meeting overall, and I think particularly for Vertex Pharmaceuticals.”

“And I think it is a really exciting time at Vertex with a lot of commercial progress and momentum. We call this a year of execution for us. And then an exciting lineup of upcoming catalysts in terms of data.”

“I will say, you know, recent news last month, we had been getting a lot of CF questions heading into competitor data that I think, you know, ended up being not as much of a concern as many have thought.”

“We have long been proud of the work we've done in cystic fibrosis, but have also long had the goal to diversify our revenue base as well as the patient groups that we can address.”